Clinical trials: Postmenopausal Osteoporosis
Osteoporosis, Post-Menopausal
PTH Comparison in Post Menopausal Women
Compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.
- Trial name
- NCT00543218
- Testing
- teriparatide 20 micrograms/day subcutaneous, calcitonin 100 IU/day subcutaneous
- Where
- 4 sites in Taiwan
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Osteopenia, Osteoporosis
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
The primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who…
- Trial name
- NCT00523341
- Testing
- Denosumab
- Volunteers
- 4,550 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis, Postmenopause
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
This study will compare the bioequivalence of two new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and medroxyprogesterone, Prempro™.
- Trial name
- NCT00381251
- Testing
- Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hip Fractures, Osteoporosis, Postmenopausal
STRONG - Study of AGN1 LOEP for the Treatment of the Contralateral Femur After Fragility Fracture
To evaluate the procedure and safety profile of the AGN1 Femoral LOEP Kit. This pilot study will be used to evaluate AGN1 Femoral LOEP treatment in a contralateral proximal femur during hip fracture repair.
- Trial name
- NCT03268356
- Testing
- AGN1 Femoral Local Osteo-Enhancement Procedure Kit
- Where
- Hong Kong
- Volunteers
- 13 people
- Sponsor
- AgNovos Healthcare, LLC
Osteopenia
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of…
- Trial name
- NCT00310531
- Testing
- Menostar (Estradiol, BAY86-5435), Raloxifene
- Volunteers
- 500 people
- Sponsor
- Bayer
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550…
- Trial name
- NCT00551174
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 781 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
This is a phase I study to analyze the effect of water and food intake on the bioavailability and pharmacodynamic of oral salmon calcitonin (SMC021) and salmon calcitonin nasal spray in post-menopausal women.
- Trial name
- NCT00395395
- Testing
- Oral salmon calcitonin, salmon calcitonin nasal spray
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Novartis
Low Bone Density, Osteopenia
Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults
No clinical trials have evaluated strontium L-lactate (SrLac), the strontium salt of the L-enantiomer of lactic acid. Therefore, this clinical study was conducted to obtain general safety and pharmacokinetic (PK) information…
- Conditions
- Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
- Trial name
- NCT03761979
- Testing
- Strontium L-lactate
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- BioLink Life Sciences, Inc.
Postmenopausal Osteoporosis
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.
- Trial name
- NCT01321723
- Testing
- PTH analog, Forsteo (Teriparatide)
- Where
- 4 sites in Denmark, Estonia
- Volunteers
- 97 people
- Sponsor
- Unigene Laboratories Inc.
Postmenopausal Osteoporosis
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
- Trial name
- NCT01668589
- Where
- 144 sites in Austria, Belgium and 2 more
- Volunteers
- 1,501 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.
- Trial name
- NCT00165698
- Testing
- menatetranone, alfacalcidol
- Where
- 5 sites in China
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Osteoporosis
A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women
SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month.
- Trial name
- NCT00532077
- Testing
- rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
- Where
- 5 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
The purpose of this study is to determine how teriparatide or denosumab affects the bone of postmenopausal women with osteoporosis after 3 months of treatment, as determined by a bone biopsy sample taken from the iliac crest…
- Trial name
- NCT01753856
- Testing
- Teriparatide, Denosumab, Demeclocycline
- Where
- 6 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.
- Trial name
- NCT00092027
- Testing
- MK0217, alendronate sodium/Duration of Treatment: 6 months
- Volunteers
- 454 people
- Sponsor
- Organon and Co
Osteoporosis
A Study for Patients With Osteoporosis
The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis
- Trial name
- NCT00414973
- Testing
- Teriparatide, Salmon Calcitonin
- Where
- 5 sites in China
- Volunteers
- 364 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.
- Trial name
- NCT04664959
- Testing
- SB16 (Proposed Denosumab Biosimilar), Prolia® (Denosumab)
- Where
- 5 sites in Poland
- Volunteers
- 457 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Osteoporosis, Postmenopausal
Risedronate Sodium in Post Menopausal Osteoporosis
The primary objective is to compare subject satisfaction of once a week dosing of 35 mg Actonel to once daily dosing of 5 mg Actonel in postmenopausal osteoporotic women.
- Trial name
- NCT00453492
- Testing
- risedronate sodium
- Where
- Turkey (Türkiye)
- Volunteers
- 246 people
- Sponsor
- Sanofi
Post-menopausal Osteoporosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.
- Trial name
- NCT01224717
- Testing
- PTH134, Forsteo
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 104 people
- Sponsor
- Novartis
Osteoporosis
A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.
The first purpose of this study is to determine if taking SB-751689 along with Rosuvastatin (CRESTOR) or Atorvastatin (LIPITOR) will change how Rosuvastatin or Atorvastatin are absorbed and eliminated from the body.
- Trial name
- NCT00388596
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline